(1998) Clinical trials of type I and in vitro studies of type II immunoadsorbents for systemic lupus erythematosus therapy. Artif Organs 22: 644-650.Kong D L, Chen C Z, Lin E F, Yu Y T (1998) Clinical trials of type I and invitro studies of typeⅡ immunoadsorbents for systemic ...
A number of type I interferon and type I interferon pathway blocking therapies are currently in clinical trials, the results of which are promising thus far. This Review provides an overview of the many ways in which the type I interferon system affects rheumatic diseases. This is a preview ...
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal between treatment risks and benefits may differ substantially between large identifiable patient subgroups; the "average" benefit observed in the summary result... DM Kent,PM Rothwell,JP Ioannidis,... - 《Trials...
Pancreatic islet cells have unexpected plasticity; however, the magnitude and clinical relevance of this phenomenon in humans remains to be determined. A substantial fraction of T1DM-associated genetic variants act at the β-cell level but only become manifest upon immune-mediated islet cell perturbatio...
Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions Background Large deletions of the NF1 gene region occur in ~5% of patients with neurofibromatosis type-1 (NF1) and are associated with particularly severe ... VF Mautner,L ...
Interim results of a phase I/II clinical trial of a DNA plasmid vaccine (BHT-3021) for type 1 diabetesare graphed and the mean change from baseline ... J Ludvigsson 被引量: 0发表: 0年 Report of a Consultation on the Optimization of Clinical Challenge Trials for Evaluation of Candidate ...
The research addresses important gaps in the evidence base for the nutritional management of type 2 diabetes by providing data on potential benefits and adverse effects of different levels of carbohydrate intake. Trial registration ClinicalTrials.gov NCT05237128. Registered on February 11, 2022...
Insulin icodec is a once-weekly basal insulin that may improve treatment acceptance and adherence by reducing the number of basal insulin injections from at least 365 per year to 52 per year.3 Clinical trials have demonstrated that icodec has a long half-life of approximately 1 week, with phas...
Type 1 Diabetes TrialNet Study Group is a clinical trials network funded by the National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, and The Eunice Kennedy Shriver National ...
Adjunctive mealtime use of the amylin analog pramlintide improves postprandial hyperglycemia in patients with type 1 diabetes. This post hoc analysis of three randomized trials evaluated whether disease duration affected responses to pramlintide. Patients received mealtime pramlintide 30 or 60 µg (n= ...